Panacos Pharmaceuticals, Inc. (PANC) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPanacos Pharmaceuticals, Inc. (PANC) trades at $0.0001. Panacos Pharmaceuticals, Inc. is an early-stage biotechnology firm focused on developing orally administered small-molecule therapeutics to combat HIV and other human viral diseases. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for PANC: PANC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Panacos Pharmaceuticals, Inc. (PANC) Healthcare & Pipeline Overview
Panacos Pharmaceuticals, Inc. is an early-stage biotechnology firm based in Watertown, MA, specializing in orally administered small-molecule therapeutics. Its research and development efforts target HIV and other viral diseases, focusing on novel viral life cycle targets like maturation and fusion inhibition, with advanced programs in HIV maturation inhibitors.
What Is the Investment Thesis for PANC?
Panacos Pharmaceuticals, Inc. presents an investment profile characterized by its early-stage biotechnology focus and inherent high-risk, high-reward potential. The company's core value proposition lies in its specialized research and development of orally administered small-molecule therapeutics targeting HIV and other viral diseases, particularly its advanced second- and third-generation programs for HIV maturation inhibition. This focus on novel targets within the viral life cycle, such as maturation and fusion, could potentially yield differentiated therapeutic candidates in areas of unmet medical need. However, the company's financial metrics underscore substantial risks. With a market capitalization of $5,367 and a profit margin of -20810.6%, Panacos Pharmaceuticals is currently operating at a significant loss, typical for pre-revenue biotech firms but indicative of a substantial burn rate. Its trading on the OTC Other tier, coupled with an unknown disclosure status, limits transparency and liquidity. Future growth is contingent upon successful progression of its pipeline through rigorous clinical trials, securing substantial funding, and potentially forming strategic partnerships. Investors should monitor any developments regarding clinical milestones, financing rounds, or strategic shifts, as these would be critical catalysts for re-evaluation.
Based on FMP financials and quantitative analysis
PANC Key Highlights
Market Capitalization: $5,367, reflecting its early-stage status and current market valuation as a micro-cap entity.
- Profit Margin: -20810.6%, indicative of significant research and development expenses typical for a pre-revenue biotechnology firm.
- Gross Margin: 100.0%, which for a company without product sales likely reflects no cost of goods sold, or revenue from grants/milestones without direct COGS.
- Employee Count: 41 employees, suggesting a lean operational structure focused on its specialized research and development activities.
- Beta: -58.99, an unusually high negative beta, which may point to low liquidity, infrequent trading, or data anomalies rather than a true inverse market correlation.
Who Are PANC's Competitors?
PANC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PANC's Key Strengths?
Specialized focus on novel HIV and viral disease targets, particularly maturation and fusion inhibition.
- Expertise in developing orally administered small-molecule therapeutics, offering potential patient convenience.
- Advanced pipeline initiatives in second- and third-generation HIV maturation inhibitors.
- Established scientific methodology for identifying critical viral targets.
What Are PANC's Weaknesses?
Early-stage company with no apparent revenue from commercial product sales.
- Significant negative profit margin (-20810.6%), indicating substantial operational losses.
- Extremely low market capitalization ($5,367) and negligible share price ($0.0001).
- OTC Other tier listing with an unknown disclosure status, limiting transparency.
What Are the Key Risks for PANC?
Financial-distress signal — its Altman Z-Score of -11.98 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-85.6%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Significant financial losses, as evidenced by a -20810.6% profit margin, indicating substantial R&D costs without offsetting revenue, posing a going concern risk.
- Extremely low market capitalization ($5,367) and negligible share price ($0.0001), suggesting severe market skepticism, potential for delisting, and limited access to capital markets.
- High attrition rate inherent in early-stage biotechnology drug development, where the vast majority of candidates do not reach commercialization, leading to potential loss of investment.
- Challenges in securing future funding necessary to advance its pipeline, given its current financial state, OTC Other tier listing, and lack of consistent public disclosure.
- Limited public disclosure due to its OTC Other tier status and unknown disclosure level, which significantly hinders investor due diligence and increases informational asymmetry.
What Threats Does PANC Face?
- High attrition rate inherent in early-stage drug development, where most candidates fail.
- Intense competition from larger pharmaceutical companies with greater financial and R&D resources.
- Stringent regulatory hurdles and lengthy approval processes for new pharmaceutical products.
- Limited financial resources and potential challenges in securing future funding to sustain R&D operations.
What Are PANC's Competitive Advantages?
- Proprietary scientific methodology focused on identifying and targeting novel processes within the viral life cycle, such as maturation and fusion.
- Specialization in orally administered small-molecule therapeutics, which can offer patient convenience and potentially broader market access.
- Advanced initiatives in second- and third-generation HIV maturation inhibitors, representing specialized pipeline development and potential for differentiated therapies.
- Accumulated intellectual property and scientific expertise derived from its research and development efforts since its founding in 1999.
What Does PANC Do?
Panacos Pharmaceuticals, Inc. operates as an early-stage biotechnology firm, established in 1999, with its primary operations situated in Watertown, Massachusetts. The company is dedicated to the research and development of orally administered small-molecule therapeutics designed to combat human immunodeficiency virus (HIV) and various other viral diseases affecting humans. Its scientific methodology is distinct, concentrating on identifying novel targets within the viral life cycle, specifically emphasizing processes such as virus maturation and fusion. This approach aims to develop innovative drugs that interfere with critical viral functions, offering new avenues for treatment. Currently, Panacos Pharmaceuticals' product portfolio includes advanced initiatives, notably second- and third-generation programs, which are centered on inhibiting HIV maturation. These programs represent the company's commitment to addressing complex viral challenges through targeted therapeutic interventions. As an early-stage entity, the company's focus remains heavily on preclinical and early clinical development, rather than commercialization. The company operates within the highly specialized biotechnology sector, aiming to carve out a niche through its specific scientific focus and drug modality. Despite its historical focus on drug development, its current market capitalization of $5,367 and negligible share price of $0.00 indicate significant operational challenges and a position as a micro-cap entity within the OTC Other tier.
What Products and Services Does PANC Offer?
- Researches and develops new orally administered small-molecule drugs.
- Focuses on creating therapeutics for human immunodeficiency virus (HIV).
- Also develops treatments for various other viral diseases affecting humans.
- Identifies novel targets within the viral life cycle to disrupt virus replication.
- Specifically concentrates on processes like virus maturation and fusion inhibition.
- Has advanced initiatives, including second- and third-generation programs, for HIV maturation inhibitors.
- Operates as an early-stage biotechnology firm.
- Headquartered and conducts its main operations in Watertown, Massachusetts.
How Does PANC Make Money?
- Primarily focused on the research and development (R&D) of drug candidates, rather than commercial sales.
- As an early-stage biotechnology firm, revenue generation is likely minimal, potentially from research grants, milestone payments from partnerships (if any), or future licensing agreements.
- Future revenue streams are contingent upon the successful clinical development, regulatory approval, and eventual commercialization of its therapeutic products.
- Currently operating at a significant loss, indicating substantial investment in R&D without corresponding product sales or significant external funding.
What Industry Does PANC Operate In?
Panacos Pharmaceuticals, Inc. operates within the highly specialized and competitive biotechnology sector, specifically targeting antiviral therapeutics. The broader healthcare industry continually seeks innovative solutions for infectious diseases, with a persistent demand for effective treatments for conditions like HIV and emerging viral threats. Panacos positions itself by focusing on orally administered small-molecule drugs and identifying novel targets within the viral life cycle, such as maturation and fusion, which differentiates its scientific approach. This niche strategy places it among numerous biotech startups and established pharmaceutical giants vying for market share in antiviral drug development. The industry is characterized by lengthy and expensive research and development cycles, high regulatory hurdles, and a significant risk of pipeline failures. Panacos's early-stage status means it is at the forefront of this high-risk, high-reward environment, where success hinges on scientific breakthroughs and substantial capital investment.
Who Are PANC's Key Customers?
- As an early-stage biotechnology firm, Panacos Pharmaceuticals, Inc. does not currently have established direct commercial customers.
- Ultimately, the target market for its developed therapeutics would be patients suffering from HIV and other viral diseases.
- Potential future customers could include healthcare providers, hospitals, and pharmaceutical companies through licensing agreements, collaborations, or product sales post-approval.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Panacos Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Watertown, United States.
Earnings Track Record
Panacos Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 0 of its last 4 reported quarters — a recurring pattern of falling short of estimates.
Financial Health
Panacos Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.98 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Panacos Pharmaceuticals, Inc. stands at -85.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -67.2%, showing how much profit it generates from its asset base. A current ratio of 5.47 indicates the company holds enough short-term assets to cover its near-term obligations.
Insider Activity
12 transactions · 1 purchases, 0 sales, 11 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
PANC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PANC Latest News
No recent news available for PANC.
PANC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PANC.
Price Targets
Wall Street price target analysis for PANC.
PANC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PANC; grades run from A+ (80-100) to F (below 30).
PANC OTC Market Information
Panacos Pharmaceuticals, Inc. trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial health, public float, and corporate governance, OTC Other companies face minimal reporting obligations. This tier is typically for companies that are not current in their reporting, are in financial distress, or have limited public information. Trading on this tier implies significantly higher risk due to lack of transparency and regulatory oversight compared to higher OTC tiers or national exchanges.
- OTC Tier: OTC Other
- Extreme Illiquidity: Very low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares without significantly impacting the price.
- Limited Information: Unknown disclosure status means a severe lack of public financial and operational information, hindering informed investment decisions.
- Price Volatility and Manipulation: Low share price and thin trading can make the stock highly susceptible to extreme price fluctuations and potential market manipulation.
- Regulatory Scrutiny: Companies on the OTC Other tier may face increased scrutiny from regulators due to limited reporting, potentially leading to trading halts or delisting.
- Financial Distress: The extremely low market cap and negative profit margin suggest significant financial challenges, including potential for bankruptcy or business cessation.
- Verify the company's current operational status and any ongoing R&D activities through independent sources.
- Attempt to locate any available financial statements or corporate filings, even if not regularly updated.
- Research the background and current involvement of management, particularly John R. Barr, beyond the provided information.
- Assess the viability of the company's scientific methodology and drug pipeline in the current biotechnology landscape.
- Understand the company's capital structure, including outstanding shares and any potential for dilution.
- Investigate any recent news regarding financing, restructuring, or strategic changes, as highlighted by AI insights.
- Consult legal and financial professionals to understand the specific risks associated with OTC Other tier investments.
- Established Founding Date: The company was founded in 1999, indicating a long-standing presence, albeit with current challenges.
- Headquarters Location: Operations are situated in Watertown, Massachusetts, a known biotechnology hub, suggesting a physical presence.
- Specific Business Focus: A clear and specialized focus on HIV and other viral diseases with a defined scientific methodology.
- Prior Drug Development Experience: AI insight notes the company's prior experience in drug development, suggesting a foundation of expertise.
- Named CEO: John R. Barr is identified as managing the company, providing a point of contact for leadership.
PANC Healthcare Stock FAQ
What revenue streams does Panacos Pharmaceuticals, Inc. have in healthcare?
As an early-stage biotechnology firm primarily focused on research and development, Panacos Pharmaceuticals, Inc. does not appear to have significant, if any, revenue streams from commercial product sales.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is strictly limited to the provided source data.
- The interpretation of 'advanced initiatives' and 'second- and third-generation programs' is based on their literal meaning within the context of early-stage drug development, without speculation on specific clinical phases or timelines.